Abstracts tagged "clinical trial"

Abstract Number: 2358 • ACR Convergence 2025
Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
Lihi Eder¹, Philip J. Mease², Iain McInnes³, M. Elaine Husni⁴, Mitsumasa Kishimoto⁵, Barbara Ink⁶, Rajan Bajracharya⁶, Jason Coarse⁷ and Fabian Proft⁸, ¹University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, ⁶UCB, Slough, England, United Kingdom, ⁷UCB, Morrisville, NC, ⁸Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A, has demonstrated clinical efficacy and safety to 3 years…
Abstract Number: 2097 • ACR Convergence 2025
Trajectories of psychological symptoms during an 18-month Diet + Exercise intervention in overweight or obese adults with osteoarthritis
Lily Alomari¹, Daniel Beavers², Kate Queen³, Shannon Mihalko⁴, Gary Miller⁴, Elena Losina⁵, Paul DeVita⁶, david Hunter⁷, Jovita Newman⁴, Sara Quandt⁸, Mary Lyles⁸, Sandra Soto³, Joanne Jordan⁹, Leigh Callahan³, Stephen Messier¹⁰ and Becki Cleveland¹¹, ¹Kansas City University, Raleigh, ²Wake forest university, Winston Salem, ³UNC, Chapel Hill, ⁴WFU, Winston Salem, ⁵BWH, Boston, MA, ⁶East Carolina University, Greenville, ⁷Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ⁸WFU, Winston-Salem, ⁹University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹⁰WFU, Winston-Salem, NC, ¹¹University of North Carolina, Chapel Hill, NC
Background/Purpose: Psychological symptoms (PsySx) have been associated with osteoarthritis (OA), and exercise may improve PsySx. We aimed to identify unique trajectories of PsySx over the…
Abstract Number: 1676 • ACR Convergence 2025
Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients With Rheumatoid Arthritis: 7-Year Data From the SELECT-COMPARE Study
Roy Fleischmann¹, Jerzy Swierkot², Patrick Durez³, Louis Bessette⁴, Xianwei Bu⁵, Irina Fish⁵, Andrew Gara⁵, Diane Caballero⁵, Charles Peterfy, MD, PhD⁶, Yoshiya Tanaka⁷ and Eduardo Mysler⁵, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Wroclaw Medical University, Department of Rheumatology and Internal Medicine, Wroclaw, Poland, ³Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ⁴Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁵AbbVie Inc., North Chicago, ⁶Spire Sciences, Inc., Boca Raton, FL, ⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: We assessed the safety and efficacy of UPA versus ADA from SELECT-COMPARE through 7-years.Methods: Patients with RA and an inadequate response to MTX were…
Abstract Number: 1465 • ACR Convergence 2025
Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
Victoria Navarro-Compan¹, Philip J. Mease², Lianne S. Gensler³, Martin Rudwaleit⁴, Yael Klionsky⁵, Jayne Stigler⁶, Erin Mancl⁷, Shirley Chen⁸, Jamie Urbanik⁹ and Xenofon Baraliakos¹⁰, ¹Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴Bielefeld University, Medical School and University Medical Centre OWL, Klinikum Bielefeld, Department of Rheumatology, Bielefeld, Germany, ⁵Division of Rheumatology, Department of Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ⁶AbbVie, Round Lake, IL, ⁷AbbVie, Chicago, IL, ⁸AbbVie, Somerset, NJ, ⁹AbbVie, Grayslake, IL, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Treatment with the oral JAK inhibitor upadacitinib (UPA) has shown efficacy and safety in patients with active axial spondyloarthritis (axSpA), including both radiographic (r-axSpA,…
Abstract Number: 1354 • ACR Convergence 2025
Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial
Hongtao Jin, Huifang Guo, Yuxiang Han and Meng Ding, The Second Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic)
Background/Purpose: Joint swelling and tenderness are major symptoms of rheumatoid arthritis (RA). This post-hoc analysis evaluated the effect of ivarmacitinib (SHR0302), a selective Janus kinase…
Abstract Number: 0657 • ACR Convergence 2025
Preliminary Analysis Of Open-Label Dose-Titration Phase Of SLE Treatment With N-Acetylcysteine (SNAC) Shows Evidence For Potential Improvement Of SLEDAI, BILAG, ADHD And Fatigue Scores In Patients With Active SLE
FNU Ruchi¹, Ioana Coman¹, Bryan Blaker¹, Lucero Blaker¹, Joy Park², Jorge Cabezas¹, Dilip Rao¹, +Xiaojing Wang¹, Aparna Godavarthy¹, Marlene Marte Furment³, Sandy Nasr⁴, Sravani Lokineni⁵, Christina Donath⁴, SARA KAHLOWN⁶, Damira Sereda¹, Binod Kc¹, Ilya Ivyanskiy¹, Bhavya Poudyal⁷, Arthur Weinstein⁸, Rosalind Ramsey-Goldman⁹, Michael Weisman¹⁰, Cynthia Aranow¹¹, Mariko Ishimori¹⁰, Kyriakos Kirou¹², Jihad Ben Gabr¹³, Sheetal Rayancha¹⁴, Nancy Olsen¹⁵, Fotios Koumpouras¹⁶, Judith Lin¹⁷, Stephen Faraone¹, Daniel Wallace¹⁸, Michael McDermott¹⁹ and Andras Perl²⁰, ¹SUNY Upstate Medical University, Syracuse, NY, ²Upstate Medical University, Syracuse, NY, ³Medical Affiliates of Cape Cod, Hyannis, MA, ⁴SUNY Upstate University Hospital, Syracuse, NY, ⁵Deaconess Hospital, Evansville, IN, ⁶Suny upstate medical university, Camillus, NY, ⁷SUNY Upstate Medical University, Cicero, NY, ⁸retired from clinical practice, volunteer academic faculty, Claremont, CA, ⁹Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Cedars-Sinai Medical Center, LOS ANGELES, CA, ¹¹Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ¹²Hospital for Special Surgery, New York, NY, ¹³Division of Rheumatology & Clinical Immunology, SUNY Upstate Medical University, Syracuse, NY, ¹⁴SUNY Upstate Medical University, Jamesville, NY, ¹⁵Penn State University/Milton S Hershey, Hershey, PA, ¹⁶Yale School of Medicine, New Haven, CT, ¹⁷Ohio State University Wexner Medical Center, Columbus, OH, ¹⁸Cedars Sinai Medical Center, Studio City, CA, ¹⁹University of Rochester Medical Center, Rochester, NY, ²⁰SUNY, Syracuse, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology with mortality still approaching 10% in 5 years. The major causes of death…
Abstract Number: 0875 • ACR Convergence 2025
Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
Lawrence Eichenfield¹, Ricardo Galimberti², Adelaide Hebert³, Wen-Hui Wang⁴, Jennifer Soung⁵, Nina Magnolo⁶, John Browning⁷, Angela Moore⁸, Mark Lebwohl⁹, Dagmar Wilsmann-Theis¹⁰, Joseph F Merola¹¹, Georgios Kokolakis¹², Dariusch Mortazawi¹³, Parbeer Grewal¹⁴, Megan Miller¹⁵, Joseph Cafone¹⁶, Shu Li¹⁷, Gigi Jiang¹⁷, Fabio Nunes¹⁷, Cynthia DeKlotz¹⁸ and Amy Paller¹⁹, ¹University of California, San Diego School of Medicine, La Jolla, CA, USA, La Jolla, CA, ²Hosp Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ³University of Texas Medical School-Houston, Bellaire, TX, USA, Bellaire, TX, ⁴Peking University Third Hospital, Haidian District, Beijing, China, Beijing, China (People's Republic), ⁵Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁶University Hospital Muenster, Muenster, Germany, Muenster, Germany, ⁷Methodist Children's Hospital, San Antonio, TX, USA, San Antonio, TX, ⁸Baylor University Medical Center, Dallas, TX, USA, Dallas, TX, ⁹Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁰University Hospital Bonn, Center for Skin Diseases, Bonn, Germany, Bonn, Germany, ¹¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ¹²Charité-Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ¹³Clinical Research Center, Remscheid, Germany, Remscheid, Germany, ¹⁴University of Alberta, Edmonton, Alberta, Canada, Edmonton, AB, Canada, ¹⁵Johnson & Johnson, San Diego, CA, USA, San Diego, CA,, CA, ¹⁶Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ¹⁷Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ¹⁸Johnson & Johnson, San Diego, CA, USA, San Diego, CA, ¹⁹Northwestern University Feinberg School of Medicine, Chicago, IL, USA, Chicago, IL
Background/Purpose: Icotrokinra (ICO), a novel targeted oral peptide, binds the interleukin (IL)-23 receptor to inhibit IL-23 signaling. ICONIC-LEAD (NCT06095115) is the first Phase 3 study…
Abstract Number: 0493 • ACR Convergence 2025
Phase I Trial in Participants with Rheumatoid Arthritis and Healthy Volunteers with CIT-013, a First in Class NETosis Inhibitor
Maarten Kraan¹, Salah Hadi², Leonie Middelink³, Renato Chirivi³, Eric meldrum³, Naomi Klarenbeek⁴ and Patrick Round³, ¹Citryll BV, Den Dolder, Netherlands, ²ICON Netherlands BV, Groningen, Netherlands, ³Citryll BV, Oss, Netherlands, ⁴CHDR, Leiden, Netherlands
Background/Purpose: Aberrant Neutrophil Extracellular Trap (NET) production contributes to the pathophysiology of multiple inflammatory and autoimmune diseases including rheumatoid arthritis (RA). We report data of…
Abstract Number: 0277 • ACR Convergence 2025
A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Ascending Doses and Food Effects of BGB-45035, a chimeric degradation activating compound (CDAC), in Healthy Participants
Vaibhav Mundra¹, Cunjing Yu², Roland Morley¹, Yuan Yuan³, Yifan Qin³, Jingjing Schneider¹, Shengnan Chen³, Zhenyuan Zhou³ and Zhen Yao², ¹BeOne Medicines USA, Inc., San Carlos, CA, ²BeOne Medicines (Beijing) Co, Ltd., Beijing, China (People's Republic), ³BeOne Medicines (Shanghai) Co, Ltd., Shanghai, China (People's Republic)
Background/Purpose: Interleukin 1 receptor associated kinase 4 (IRAK4) degradation may modulate toll-like receptor signaling and alleviate symptoms in rheumatoid arthritis and atopic dermatitis.1,2 BGB-45035, an…
Abstract Number: 2466 • ACR Convergence 2025
Efficacy and Safety Results of Zetomipzomib from the PALIZADE Phase 2b Clinical Trial in Patients with Lupus Nephritis
Richard Furie¹, Neel Anand², Shraddha Desai³, Eric Lowe⁴, Tony Muchamuel³, Kiruthi Palaniswamy², Rachel Peterson², Kathryn Ray², Zung To², Jennifer Whang² and Richard Leff⁵, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Kezar Life Sciences, Inc, South San Francisco, CA, ³Kezar Life Sciences, Inc, South San Francisco, ⁴Kezar Life Sciences, South San Francisco, CA, ⁵Richard L Leff MD LLC, Chadds Ford, PA
Background/Purpose: Zetomipzomib (zeto), a selective immunoproteasome inhibitor, has previously shown anti-inflammatory activity in patients (pts) with SLE and LN in the open-label MISSION study. The…
Abstract Number: 2356 • ACR Convergence 2025
Clinical Efficacy in Male and Female Patients With Active Psoriatic Arthritis Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies
Lihi Eder¹, Philip J. Mease², Joseph F Merola³, Alexis Ogdie⁴, Atul Deodhar⁵, Laura Coates⁶, Stefan Varga⁷, Navya Kalapala⁷, Ying-Ming Jou⁸, Eleni Vritzali⁹ and Laure Gossec¹⁰, ¹University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ⁵Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb, Princeton, ⁹Bristol Myers Squibb, Boudry, Switzerland, ¹⁰Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: PsA affects male and female patients equally; however, variations in clinical manifestations and treatment responses between sexes have been reported. Deucravacitinib is an oral,…
Abstract Number: 2086 • ACR Convergence 2025
WOMAC Physical Function and 3D MRI Bone Shape: Advancing a “Virtual” Total Knee Replacement Endpoint for Knee Osteoarthritis Clinical Trials
Dawn McGuire¹, Alan Brett², Neil Segal³, Meghan Miller⁴, David Rosen¹ and Yoshi Kumagai⁵, ¹OrthoTrophix, Inc, Foster City, CA, ²Imorphics, Manchester M²⁰ ²HJ, England, United Kingdom, ³KUMC, Kansa City, KS, ⁴OrthoTrophics, Foster City, CA, ⁵OrthoTrophix, Foster City, CA
Background/Purpose: TPX-100, a peptide derived from matrix extracellular phosphoglycoprotein (MEPE), is in development as a potential disease-modifying osteoarthritis drug (DMOAD) for mild to severe knee…
Abstract Number: 1674 • ACR Convergence 2025
A Phase 2, Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Individuals At-Risk for Future Rheumatoid Arthritis
Kevin Deane¹, Christopher Striebich², Marie Feser³, James O'Dell⁴, Judith James⁵, Jeffrey Sparks⁶, John Davis⁷, Jonathan Graf⁸, Maureen McMahon⁹, Elizabeth Solow¹⁰, Lindsy Forbess¹¹, Athan Tiliakos¹², Elena Schiopu¹³, David Fox¹⁴, Maria I. ("Maio") Danila¹⁵, Diane Horowitz¹⁶, Jonathan Kay¹⁷, Colin Strickland³, Joel Guthridge⁵, Cristina Arriens⁵, Jennifer Grossman¹⁸, Kristen Demoruelle¹⁹, Elizabeth Bemis³, Ashley Frazer-Abel³, Chelsie Fleischer²⁰, Ted Mikuls⁴, Melissa Greenleaf²¹, Kate York²², Sarah Walker²³, Lynette Keyes-Elstein²³, Margie Byron²³, Janel Fedler²⁴, Ellen Goldmuntz²⁵ and V. Michael Holers²⁶, ¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²University of Colorado, Aurora, CO, ³University of Colorado Anschutz Medical Campus, Aurora, CO, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Mayo Clinic, Rochester, MN, ⁸UCSF, San Francisco, CA, ⁹UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁰UT Southwestern Medical Center, Dallas, TX, ¹¹Cedars-Sinai Medical Center, Los Angeles, CA, ¹²Emory University, Roswell, GA, ¹³Medical College of Georgia at Augusta University, Martinez, GA, ¹⁴University of Michigan, Dexter, MI, ¹⁵University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ¹⁶Northwell Health, Jericho, NY, ¹⁷UMass Chan Medical School, Worcester, MA, ¹⁸UCLA, Sherman Oaks, CA, ¹⁹University of Colorado Anschutz Medical Campus, Golden, CO, ²⁰University of Colorado Denver, Aurora, CO, ²¹National Institutes of Health, Rockville, MD, ²²Rho, Inc, Durham, NC, ²³Rho, Inc., Durham, NC, ²⁴Rho, Inc., Salem, IA, ²⁵NIAID/ NIH, Washington, DC, ²⁶University of Colorado, Denver, CO
Background/Purpose: Individuals with elevations of serum anti-cyclic citrullinated peptide (anti-CCP) antibodies are at-risk for rheumatoid arthritis (RA). Identification of interventions to prevent RA in anti-CCP-positive…
Abstract Number: 1461 • ACR Convergence 2025
Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis And Persistent Pain: Results From a Randomized Controlled Trial
David Kiefer¹, Yade Sonkaya², Dietmar Krause³, Markus Voglau⁴, Bernhard Mintrop⁵, Imke Redeker⁶, Xenofon Baraliakos⁷ and Uta Kiltz⁷, ¹Ruhr-Universität Bochum; Private practice of rheumatology, Hattingen, Germany, Herne, Germany, ²Ruhr-Universität Bochum, Herne, Germany, ³Elisabeth-Gruppe, Herne, Germany, Essen, Germany, ⁴myself, Oldenburg, Germany, ⁵Private rheumatology practice, Hattingen, Germany, ⁶Ruhr University Bochum, Bochum, Germany, ⁷Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is often associated with persistent pain despite effective anti-inflammatory treatment, substantially impacting patients' quality of life. Digital health applications (DiGAs) provide…
Abstract Number: 1270 • ACR Convergence 2025
Increasing Participation in the FT819 Cell Therapy Trial Amongst People Living with Lupus: A Focus Group Study
Joy Buie¹, Safoah Agyemang¹, Andrew Henry², Andrew BitMansour³, Vaneet Sandhu⁴, Debra Zack⁵ and Michael Fisher¹, ¹Lupus Foundation of America, Washington, DC, ²Fate Therapeutics, Inc., San Diego, CA, ³Fate Therapeutics, Inc., San Carlos, CA, ⁴Fate Therapeutics, Inc., San Diego, ⁵Fate Therapeutics, San Diego
Background/Purpose: Clinical trials exploring the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy for lupus are growing. Challenges linked to recruitment for CAR…

« Previous Page
1
…
7
8
9
10
11
…
55
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].